News
By Stephanie Brown HealthDay ReporterTHURSDAY, July 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
The U.S. Food and Drug Administration released more than 200 of its so-called complete response letters from its archive on ...
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are ...
Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial ...
FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.
The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...
The U.S. FDA publishes over 200 complete response letters to enhance transparency within the agency. Read more here.
The FDA issues complete response letters when it determines that it can't approve an application in its current form, mostly due to safety and efficacy concerns, manufacturing deficiencies or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results